



Executive Summary

Industry

Biotechnology, Drug Development

Management

- Ran Vigdor, LL.B, MBA, CEO
- Beatriz Palacios, PharmD, PhD, Development Director
- Nicholas L. Occleston, PhD Discovery Director
- Javier Cascos, CFO

Recent Achievements

- Among a handful of Spanish companies to **receive FDA Approval for First-in-Man study** (September, 2010)
- Chosen to be **one of the top 5 biotechnology investment opportunities in Spain** (BioSpain October, 2010)

Current Shareholders

- Cross Road Biotech, S.A. S.C.R.
- Fondo Tecnológico Seguranza
- Real De Vellón, S.A. S.C.R.
- Ade Gestion Sodical SGEGR
- Oncopharma ,S.L.



Business Description: Traslational Cancer Drugs Pharma S.L (“TCD” or the “Company”) is a biotechnology corporation focused on the discovery, development and commercialization of **innovative therapies** that address unmet medical needs in the field of Oncology.

Strategy: TCD’s strategy is to **identify, evaluate and in-license breakthrough discoveries** and to rapidly advance them through the completion of Phase II of the Regulatory process. This is done by leveraging resources through collaborations and outsourcing via premier Contract Research Organizations, resulting in an **efficient, flexible and effective process**. Value to shareholders is generated by royalty-bearing licensing agreements.

First Target: TCD’s leading target is Choline Kinase Alpha (ChoK α), an enzyme regulating the production of phosphatidylcholine (a key building block in the formation of the cell’s membrane). TCD has demonstrated that ChoK α is a treatment target of unique quality. Not only can ChoK α be used for treatment of patients suffering from a **broad variety of tumors** but also inhibition of ChoK α while merely arresting temporarily the life cycle of normal cells is toxic to cancer cells.

First Product: TCD-717 is the Company’s leading product. This **first-in-class**, precisely-targeted ChoK α inhibitor is a small molecule that has demonstrated favorable therapeutic index in various cancer types both *in-vitro* and *in-vivo*.



Key Advantages

- Experienced team
- Virtual cost effective structure
- Clear need market and industry need
- Network of research institutions

Number of Employees 7

Previous Rounds

- Invested to date: ≈ €8,400,000
- Seed Round (Class A) €754,987
- 1st Round (Class B) €1,650,000
- 2nd Round (Class B) €6,000,000

Investment Required

- €5 million
- Minimum investment - €500,000

Use of Funds

- Develop TCD-717 to phase II
- Pipeline expansion – in-licensing and development of new programs

Status: The *FDA has approved the Company's IND application* to initiate Phase I clinical study for TCD-717 as a treatment for solid tumors. The study will take place in two medical center in the US. The cumulative potential market in Europe and the US for TCD-717 is over 880,000 new patients a year in various indications, with sales expected to be in the billions.

Pipeline: TCD is currently positioning itself as a Spain's *Partner of Choice* for Oncology drug discovery and development opportunities. The aim of the Company is to build its pipeline through in-licensing of cutting edge technology, with clear commercial rational after proof-of-concept has been reached. In doing so TCD is capitalize on the high quality innovative research currently conducted in Spain and the limited early stage commercialization and funding options currently available to researchers and early stage projects.

A View to 2013: by the end of 2013 TCD would have one drug candidate in Phase II (TCD-717), two new programs with drug candidates entering pre-clinical studies (regulatory toxicology and safety) and two programs in process of candidate selection.

The Opportunity: ChoK α and TCD-717 with large target markets and strong IP position insure value to shareholders. TCD's strong management team with extensive experience and expertise together with unique relationship with key research institutions in Spain and the promise of new discoveries offer shareholders untapped potential.



For more information:

info@tcdpharma.com

Visit us at www.tcdpharma.com

